AMG 157

Drug Profile

AMG 157

Alternative Names: AMG-157; Anti-TSLP MAb; MEDI-9929

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bispebjerg Hospital; Lund University; MedImmune; University of Copenhagen; University of Newcastle, Australia
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis

Most Recent Events

  • 01 Mar 2017 Medimmune completes a phase II trial in Asthma in USA, Bulgaria, Czech Republic, Hungary, Israel, Japan, Latvia, Lithuania, Serbia, South Africa, Ukraine and Slovakia (NCT02054130; EudraCT2013-003269-33)
  • 01 Aug 2016 Phase-II clinical trials in Asthma (Treatment-experienced) in Denmark (IV) (NCT02698501)
  • 01 Jul 2016 Amgen and MedImmune completes the ALLEVIAD phase IIa trial in Atopic dermatitis in USA, Hungary, Canada, New Zealand, Germany and Australia (NCT02525094)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top